Clinical analysis of prophylactic lamivudine reduced hepatitis B virus reactivation in patients with B-cell non-Hodgkin 's lymphoma receiving rituximab combination chemotherapy
10.3760/cma.j.issn.1009-9921.2012.09.004
- VernacularTitle:拉米夫定预防B细胞非霍奇金淋巴瘤患者利妥昔单抗化疗后乙型肝炎病毒再激活的临床分析
- Author:
Jianyi ZHU
;
Fangyuan CHEN
;
Fei XIAO
;
Honghui HUANG
;
Hua ZHONG
;
Xiaofeng HAN
;
Tin WANG
;
Lan XU
;
Lu ZHONG
;
Beiwen NI
- Publication Type:Journal Article
- Keywords:
Lymphoma,B-cell;
Rituximab;
Hepatitis B virus;
Reactivation;
Lamivudine
- From:
Journal of Leukemia & Lymphoma
2012;21(9):524-527
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the safety of rituximab combination chemotherapy in the treatment of B-cell non-Hodgkin' s lymphoma (B-NHL) complicated with hepatitis B virus (HBV) infection,and assess the incidence of HBV reactivation reduced by prophylactic lamivudine.Methods A retrospective study of HBV-related markers,HBV-DNA and liver function was performed before and after rituximabcontaining treatment in B-NHL patients.Thirty nine B-NHL patients with HBcAb(+)/HBsAb(-) were divided into prophylactic group (14 cases) and control group (25 cases).The incidences of HBV reactivation,functional damage of liver were measured.Results Among the 108 B-NHL patients who received rituximab combinatio nchemotherapy,15 (13.89 ％) were HBsAg (+) and 39 (36.11％) HBsAg (-) / HBcAb (+).Of the 15 HBsAg (+)patients,2 (13.3 ％) experienced reactivation of HBV.The prevalence of HBV reactivation was 7.7 ％(1/13) in patients who received prophylactic antiviral treatment and 50 ％ (1/2) in those who did not receivelamivudine.Among the 39 HBsAg (-) / HBcAb (+) patients,3 cases (7.7 ％) experienced reactivation of HBV.The prevalence of HBV reactivation was 0 in patients who receivcd prophylactic lamivudine treatment and 12 ％ (3/25) in those who did not receive this antiviral drug.Conclusion Prophylactic lamivudine before rituximab combination chemotherapy can reduce HBV reactivation obviously.
